- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03699722
A Women-Focused PrEP Intervention (Just4Us)
Developing a Women-Focused PrEP Intervention for HIV Prevention
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The HIV epidemic among women in the US is a major public health issue and many women at high risk for acquiring HIV infection are not aware of pre-exposure prophylaxis (PrEP), an efficacious, self-administered, woman-controlled, HIV prevention product. In 2014, the Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) issued guidelines for evaluating and prescribing PrEP for women at high risk for acquiring HIV. Yet, there are currently no interventions in the US to promote PrEP uptake among high risk women.
The objective of this study is to evaluate an intervention to promote PrEP uptake in two large metropolitan areas with local HIV rates that greatly exceed the national average but with different PrEP public policy and access landscapes. The investigators hypothesize that a theory-based, contextually relevant behavioral intervention combined with linkage to health care and social services, with text message support for adherence, would be feasible and acceptable and would improve PrEP uptake among high risk women.
Eligible women will be recruited primarily via face-to-face recruitment and respondent driven sampling. For respondent driven sampling, enrolled participants will be given three (3) coupons to be given to women in her social network who she thinks would be interested in joining the study. If the person referred attends a baseline visit, the referring participant will receive $10. Assessment of eligibility will be conducted by telephone or in-person. Participant initials and phone number will be recorded on the form. Eligible participants will be scheduled for a study visit at a day and time convenient for her. Study visits will be held at UPenn School of Nursing (Philadelphia) or the New York Blood Center Project Achieve office (NYC) or at a mutually agreeable location in the community that provides a private place for study procedures.
For the randomized trial, the investigators will conduct a study among 80 women to evaluate the feasibility and acceptability of the intervention. Each of the two study sites will enroll forty (40) women; thirty (30) participants will receive the theory-based, contextually tailored education and activities intervention and ten (10) participants will be randomized to the information only control group.
Prior to administering any study procedures women participants will participate in an informed consent process. During the informed consent process research staff will explained some participants will receive the education and activities intervention and some participants will receive information control group. After their questions are answered and participant signs the consent form, all participants will complete a computer-based baseline assessment and receive a rapid HIV test. All participants (control and intervention) will sign a release of information form authorizing the study team to contact the PrEP health care site for the minimal information needed to assess if PrEP was prescribed.
Randomization will be performed centrally by the project statistician, and implemented using opaque sealed envelopes. Envelopes will be numbered and shipped to each study site. Balance between arms will be maintained by use of randomly permutated blocks with unequal block sizes of 4 and 8 (to allow for the 3:1 randomization ratio), and with stratification by site (2 strata). At each site, a sealed envelope will be opened, in consecutive order, indicating study arm.
Upon completing the computer-based survey, participants randomized to the education and activities intervention arm will receive an individual tailored in-person session, conducted by a trained counselor/navigator (CN). Participants will also be asked to design simple personalized text messages for asking about PrEP initiation and PrEP adherence reminders once starting PrEP. Finally, the CN will also coordinate with the participant the best day and time to schedule her four (4) follow-up phone calls. During the phone calls, the CN will reinforce skills for PrEP uptake, review the action plan regarding identified vulnerability factors that could interfere with PrEP uptake and reinforce strategies to access referrals.
Participants randomized to the information only arm will meet with the counselor/navigator to review resources regarding PrEP and receive a list of providers/clinics prescribing PrEP.
After the session, participants will complete a post-session computer-bases survey to assess social-cognitive variables targeted in the intervention. Participants will also complete a Participant's Brief Satisfaction Questionnaire to provide feedback on the session.
All participants will be compensated $50.00 All participants enrolled will return to the study site for a three (3) month follow-up study visit to complete the computer-based survey and a questionnaire evaluating her experience navigating through the process to obtain provider appointment, medical assessment for PreP, prescription and taking PreP. Participants will be compensated $50.00 upon completing the three (3) month follow-up study visit.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Anne Teitelman
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- female at birth and identify as female
- aged 18-55;
- report unprotected vaginal or anal sex with a male partner OR any injection drug use in the past 6 months;
- live or have sex in a high risk area or are recruited into the study by someone who lives or has sex in a high risk area;
- understand and read English;
- not known to be HIV-infected;
- are willing to consider a daily pill with low rates of mild side effects to prevent HIV;
- have access to a mobile phone.
- report at least one of the following as 'yes' or 'do not know': current male partner who injects drugs or has sex with men; current male partner who is HIV infected; current male partner who was incarcerated in the last 6 months OR report at least one of the following as 'yes': shared injection equipment in last 6 months; in methadone, buprenorphine or suboxone treatment program in past 6 months; exchange sex for money, drugs, other goods in last 6 months; powder cocaine, crack use, methamphetamines, or ecstasy >1x/week in last 6 months; Chlamydia, syphilis, gonorrhea diagnosed or newly diagnosed genital herpes in last 6 months; alcohol abuse in last 6 months (defined as a score of 2 or higher on the CAGE36); has 3 or more male partners.
Exclusion Criteria:
- currently using PrEP
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Education + Activities
12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider.
Up to 4 follow-up phone calls to reinforce strategies.
Text messaging for support PrEP adherence.
|
Format:Video; discussion; information handouts; facilitated referral
|
|
Comparatore attivo: Information
PrEP information brochures, frequently asked questions and questions to ask provider.
Listing of local PrEP providers.
|
Format: Information handouts
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Intervention Fidelity
Lasso di tempo: baseline session
|
Evaluation of fidelity behavior for each module by site coordinator after listening to audio recordings of intervention sessions using a rating form with 90% evaluation items must be 4s or 5s on a 5-point Likert scale.
|
baseline session
|
|
Participant Acceptability of intervention
Lasso di tempo: baseline and 3 months
|
At least 80% of participants report moderate or higher levels of acceptability: based on participants' indicating favorable responses indicated by 4s and 5s on a 5 point Likert scale on the Brief Satisfaction Questionnaire
|
baseline and 3 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PrEP uptake behavior
Lasso di tempo: 3 months
|
PrEP uptake behavior (Preliminary Impact) as reported by self report at 3 months
|
3 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 1R34MH108437-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Education + Activities
-
Nordsjaellands HospitalLund University; Region Capital Denmark; Ostfold University College; University College... e altri collaboratoriReclutamentoOspedaleDanimarca, Norvegia, Svezia
-
Tokat Gaziosmanpasa UniversityCompletatoStigmatizzazione | Funzionalità | Supporto tra pari | Disturbi mentali cronici | Formazione sulle abilità psicosociali | IntuizioneTacchino
-
Tulane UniversityUniversity of Alabama at Birmingham; Louisiana State University Health Sciences... e altri collaboratoriTerminatoCOVID-19 | Lupus eritematoso sistemicoStati Uniti
-
National University of Ireland, Galway, IrelandUniversity College Hospital Galway; Brothers of Charity Services Galway IrelandNon ancora reclutamentoDisabilità intellettive (F70-F79) | Educazione alla prevenzione e alla consapevolezza del cancro | Consapevolezza del cancro al senoIrlanda
-
Fundacion para la Investigacion y Formacion en...Iscrizione su invitoBPCO (broncopneumopatia cronica ostruttiva)Spagna
-
Saglik Bilimleri UniversitesiNon ancora reclutamentoInvecchiamento | Anziani fragili | Sindromi geriatriche
-
University of Arkansas, FayettevilleNational Cancer Institute (NCI); University of California, Los Angeles; Thomas... e altri collaboratoriAttivo, non reclutanteMalattie prevenibili da vaccino | Papilloma-virus umanoStati Uniti
-
Centers for Disease Control and PreventionCompletatoInfezioni da HIV | Epatite CStati Uniti
-
Cukurova UniversityNon ancora reclutamentoGravidanza | Esercizio | Realta virtualeTacchino
-
Chia-Tzu LineCompletatoDiabete mellito di tipo 2 (T2DM) | Pazienti diabetici, cura di sé, basato sull'intelligenza artificiale, autoefficaciaCina